Mayne Pharma Group Limited (MYX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and thank you for joining Maine Pharma's One Age Fiscal 26 results presentation. Today, we will cover the group financial outcome for the half, then take you through each segment, women's health, dermatology, and international, before finishing with our Fiscal 26 focus and outlook. As investors will appreciate, we have already provided a set of our unaudited numbers within our presentation at the company's 2025 Annual General Meeting on 29 January, 2026. Before we begin the formal aspects of today's presentation, as we announced to the market this morning, Main Pharma is undertaking a planned and orderly leadership transition, with Sean Patrick O'Brien stepping down as Chief Executive Officer and Managing Director, and with me having been appointed Chief Executive Officer, both effective from February 21. This transition is part of the board structured succession process and is designed to maintain momentum and execution with continuity of strategy, governance, and financial discipline. Importantly, the business remains stable with a strong, experienced leadership team in place across our key functions and business units. And we are continuing to operate exactly as planned with a focus on performance, outcomes, and disciplined allocation of capital. I want to acknowledge and thank Sean for his contribution and partnership with me through a period of meaningful change. And I'm pleased that he will remain available to the board in an advisory capacity to support an orderly transition for me as CEO. I would now like to turn over to Sean, who was with me on today's call, to make some remarks on the transition. Thanks, Aaron. It's been a pleasure to work with you over the last three and a half years at Maine Pharma. Investors should note this is a ...